Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 setmelanotide trial in Bardet-Biedl syndrome and Alström syndrome with obesity
2018-004058-11Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Mar 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of setmelanotide in Bardet–Biedl syndrome (BBS), Alström syndrome (ALMS) and obesity, sponsored by Rhythm Pharmaceuticals. Primary endpoint: Body weight responder rate in patients aged 12 years or older. Started Mar 2019; status: completed.
02
Drugs
setmelanotide
03
Conditions
Bardet–Biedl syndrome (BBS)Alström syndrome (ALMS)obesity
Beyond the preview
Go deeper on 2018-004058-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004058-11.